The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Surgical site infections and antimicrobial resistance remain major challenges globally
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Subscribe To Our Newsletter & Stay Updated